<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="de53523f-624f-492d-8d2f-027bbd7ce5f3"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to useÂ ERIBULIN MESYLATE INJECTION safely and effectively. See full prescribing information for ERIBULIN MESYLATE INJECTION.</content>
      <br/>
      <br/>
      <content styleCode="bold">ERIBULIN MESYLATE injection, for intravenous use</content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 2010</content>
   </title>
   <effectiveTime value="20250307"/>
   <setId root="8a81f3e9-ac52-4f98-bf62-da7974d012b3"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="542977621" root="1.3.6.1.4.1.519.1"/>
            <name>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="542977621" root="1.3.6.1.4.1.519.1"/>
                        <name>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71731-4171" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71731-4171" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71731-4171" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71731-4171" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="421265144" root="1.3.6.1.4.1.519.1"/>
                        <name>Lianyungang Runzhong Pharmaceutical Co., Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71731-4171" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="afb9f2ba-cb89-478e-8634-546c40564ad6"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250307"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71731-4171" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Eribulin Mesylate</name>
                        <formCode code="C42946" displayName="INJECTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Eribulin Mesylate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="AV9U0660CW" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ERIBULIN MESYLATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="LR24G6354G" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ERIBULIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="N762921K75" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NITROGEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="2"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" displayName="VIAL, SINGLE-DOSE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71731-4171-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250304"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA218743" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250304"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="95e12102-8ed0-477c-9431-6df13f47e246"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1 </content>
                  <content styleCode="bold">INDICATIONS AND USAGE</content>
               </title>
               <effectiveTime value="20250312"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. (<linkHtml href="#_1_1_Metastatic_Breast">1.1</linkHtml>)</item>
                           <item>UnresectableÂ or metastatic liposarcoma who have received a prior anthracycline-containing regimen. (<linkHtml href="#_1_2_Liposarcoma">1.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_1_1_Metastatic_Breast">
                     <id root="d7cd173a-951e-49ab-9795-83284d65e534"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.1 </content>
                        <content styleCode="bold">Me</content>
                        <content styleCode="bold">tastatic Breast Cancer</content>
                     </title>
                     <text>
                        <paragraph>Eribulin mesylate injection isÂ indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Â Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic settingÂ <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_14_1_Metastatic_Breast">Clinical Studies (14.1)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section ID="_1_2_Liposarcoma">
                     <id root="7a3291a0-1fc6-47e4-a22c-e9dc29f88ba6"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.2 </content>
                        <content styleCode="bold">Liposarcoma </content>
                     </title>
                     <text>
                        <paragraph>Eribulin mesylate injection is indicated for the treatment of patients with unresectable or metastatic liposarcomaÂ who have received a prior anthracycline-containing regimen <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_14_2_Liposarcoma">Clinical Studies (14.2)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="4722b0af-f216-4210-8c08-2d8c528dc7dc"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2 </content>
                  <content styleCode="bold">DOSAGE AND ADMINISTRATION</content>
               </title>
               <effectiveTime value="20250312"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Administer 1.4 mg/m<sup>2</sup> intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. (<linkHtml href="#_2_1_Recommended_Dose">2.1</linkHtml>) </item>
                           <item>Reduce dose in patients with hepatic impairment or with moderate or severe renal impairment. (<linkHtml href="#_2_1_Recommended_Dose">2.1</linkHtml>)</item>
                           <item>Do not mix with other drugs or administer with dextrose-containing solutions. (<linkHtml href="#_2_3_Instructions_for">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_2_1_Recommended_Dose">
                     <id root="6542adae-64a0-411c-95dd-08d301afde24"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1 </content>
                        <content styleCode="bold">Recommended Dose</content>
                     </title>
                     <text>
                        <paragraph>The recommended dose of eribulin mesylate injection is 1.4 mg/m<sup>2</sup> administered intravenously over 2Â toÂ 5Â minutes on Days 1 and 8 of a 21-day cycle.</paragraph>
                        <paragraph>The recommended dose of eribulin mesylate injection in patients with mild hepatic impairment (Child-Pugh A) is 1.1 mg/m<sup>2</sup> administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle <content styleCode="italics">[</content>
                           <content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_6_Hepatic_Impairment">Use in Specific Populations (8.6)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>The recommended dose of eribulin mesylate injection in patients with moderate hepatic impairment (Child-Pugh B) is 0.7 mg/m<sup>2</sup> administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle <content styleCode="italics">[</content>
                           <content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_6_Hepatic_Impairment">Use in Specific Populations (8.6)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>The recommended dose of eribulin mesylate injection in patients with moderateÂ orÂ severe renal impairment (creatinine clearance (CLcr) 15-49 mL/min) is 1.1 mg/m<sup>2</sup> administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle <content styleCode="italics">[</content>
                           <content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_7_Renal_Impairment">Use in Specific Populations (8.7)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_2_Dose_Modification">
                     <id root="45272a71-2a1d-4f75-a083-29fd2bcc5cf5"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2 </content>
                        <content styleCode="bold">Dose Modification </content>
                     </title>
                     <text>
                        <paragraph>Assess for peripheral neuropathy and obtain complete blood cell counts prior to each dose.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Recommended dose delays</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Do not administer eribulin mesylate injection on Day 1 or Day 8 for any of the following:<br/>-Â ANC &lt; 1,000/mm<sup>3</sup>
                              <br/>-Â Platelets &lt; 75,000/mm<sup>3</sup>
                              <br/>-Â Grade 3 or 4 non-hematological toxicities.</item>
                           <item>The Day 8 dose may be delayed for a maximum of 1 week.<br/>- If toxicities do not resolve or improve to â¤ Grade 2 severity by Day 15, omit the dose. <br/>- If toxicities resolve or improve to â¤ Grade 2 severity by Day 15, administer eribulin mesylate injection at a reduced dose and initiate the next cycle no sooner than 2 weeks later.</item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Recommended dose reductions</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>If a dose has been delayed for toxicity and toxicities have recovered to Grade 2 severity or less, resumeÂ eribulin mesylate injection at a reduced dose as set out in Table 1.</item>
                           <item>Do not re-escalateÂ eribulin mesylate injection dose after it has been reduced.</item>
                        </list>
                        <table>
                           <caption>Table 1: RecommendedÂ Dose Reductions</caption>
                           <colgroup>
                              <col width="396"/>
                              <col width="180"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Event Description</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Recommended Eribulin Mesylate InjectionÂ </content>
                                    <content styleCode="bold">Dose</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Permanently reduce the 1.4 mg/m</content>
                                    <content styleCode="bold">
                                       <sup>2</sup>
                                    </content>
                                    <content styleCode="bold">Â eribulin mesylate injection dos</content>
                                    <content styleCode="bold">e for any of theÂ </content>
                                    <content styleCode="bold">following:</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1.1 mg/m<sup>2</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â ANC &lt;500/mm<sup>3</sup> for &gt;7 days</td>
                                 <td styleCode="Lrule Rrule" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â ANC &lt;1,000 /mm<sup>3</sup> with fever or infection</td>
                                 <td styleCode="Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Platelets &lt;25,000/mm<sup>3</sup>
                                 </td>
                                 <td styleCode="Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Platelets &lt;50,000/mm<sup>3</sup> requiring transfusion</td>
                                 <td styleCode="Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Non-hematologic Grade 3 or 4 toxicities</td>
                                 <td styleCode="Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Omission or delay of Day 8Â eribulin mesylate injection dose in previous cycle for toxicity</td>
                                 <td styleCode="Lrule Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Occurrence </content>of any event requiring permanent dose reduction while receiving 1.1 mg/m<sup>2 </sup>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">0.7 mg/m<sup>2</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Occurrence</content> of any event requiring permanent dose reduction while receiving 0.7 mg/m<sup>2 </sup>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">DiscontinueÂ eribulin mesylate injection</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2">ANC = absolute neutrophil count. <br/>Toxicities graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_3_Instructions_for">
                     <id root="bc5386fc-75a5-4e8e-a661-698e0b330e23"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.3 </content>
                        <content styleCode="bold">Instructions for Preparation and Administration </content>
                     </title>
                     <text>
                        <paragraph>Aseptically withdraw the required amount of eribulin mesylate injection from the single-dose vial and administer undiluted or diluted in 100 mL of 0.9% Sodium Chloride Injection, USP.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Do not dilute in or administer through an intravenous line containing solutions with dextrose. </content> Do not administer in the same intravenous line concurrent with the other medicinal products.</paragraph>
                        <paragraph>Store undilutedÂ eribulin mesylate injection in the syringe for up to 4 hours at room temperature or for up to 24Â hours under refrigeration at 4Â°C (40Â°F). Store diluted solutions ofÂ eribulin mesylate injection for up to 4Â hours at room temperature or up to 24Â hours under refrigeration at 4Â°C (40Â°F).</paragraph>
                        <paragraph>Discard unused portions of the vial.</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_3_DOSAGE_FORMS">
               <id root="b2098b86-5e10-4a24-8239-e5730e913789"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3 </content>
                  <content styleCode="bold">DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph>Injection:Â Â 1 mg/2 mL (0.5 mg/mL)Â eribulin mesylate is a clear, colorless, sterile solution in a single-dose vial.Â </paragraph>
               </text>
               <effectiveTime value="20250310"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 1 mg per 2 mL (0.5 mg per mL)Â eribulin mesylateÂ in a single-dose vial (<linkHtml href="#_3_DOSAGE_FORMS">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_4_CONTRAINDICATIONS">
               <id root="8ca54e12-5545-4a20-93cf-7b4a3fc94e6e"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4 </content>
                  <content styleCode="bold">CONTRAINDICATIONS </content>
               </title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250307"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (<linkHtml href="#_4_CONTRAINDICATIONS">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="88f88d39-1aa4-4135-ad6b-e0e6a4683327"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5 </content>
                  <content styleCode="bold">WARNINGS AND PRECAUTIONS</content>
               </title>
               <effectiveTime value="20250312"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Neutropenia</content>: Â Monitor peripheral blood cell counts and adjust dose as appropriate. (<linkHtml href="#_5_1_Neutropenia">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Peripheral Neuropathy</content>: Â Monitor for signs of neuropathy. Manage with dose delay and adjustment. (<linkHtml href="#_5_2_Peripheral_Neuropathy">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Embryo-Fetal Toxicity</content>:Â Â Can cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception. (<linkHtml href="#_5_3_Embryo_Fetal_Toxicity">5.3</linkHtml>, <linkHtml href="#_8_1__Pregnancy">8.1</linkHtml>, <linkHtml href="#_8_3_Females_and">8.3</linkHtml>) </item>
                           <item>
                              <content styleCode="underline">QT Prolongation</content>:Â Â Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid in patients with congenital long QT syndrome. (<linkHtml href="#_5_4_QT_Prolongation">5.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_5_1_Neutropenia">
                     <id root="cc3b4588-1496-4335-8251-76c8e5c62805"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1 </content>
                        <content styleCode="bold">Neutropenia </content>
                     </title>
                     <text>
                        <paragraph>In Study 1, severe neutropenia (ANC &lt; 500/mm<sup>3</sup>) lasting more than one week occurred in 12% (62/503) of patients with metastatic breast cancer, leading to discontinuation in &lt;1% of patients.Â  Febrile neutropenia (fever â¥38.5Â°C with Grade 3 or 4 neutropenia) occurred in 5% (23/503) of patients; two patients (0.4%) died from complications of febrile neutropeniaÂ <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1__Clinical">Adverse Reactions (6.1)</linkHtml>
                           </content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                        <paragraph>In Study 1, patients with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;Â 3 Ã ULN (upper limit of normal) experienced a higher incidence of Grade 4 neutropenia and febrile neutropenia than patients with normal aminotransferase levels. Patients with bilirubin &gt;Â 1.5 Ã ULN also had a higher incidence of Grade 4 neutropenia and febrile neutropenia.</paragraph>
                        <paragraph>In Study 2, severe neutropenia (ANC &lt; 500/mm<sup>3</sup>) lasting more than one week occurred in 12% (26/222) of patients with liposarcoma or leiomyosarcoma. Febrile neutropenia occurred in 0.9% of patients treated withÂ eribulin mesylateÂ and fatal neutropenic sepsis in 0.9% [see <linkHtml href="#_6_1__Clinical">Adverse Reactions (6.1)</linkHtml>].</paragraph>
                        <paragraph>Monitor complete blood counts prior to each dose; increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias. Delay administration ofÂ eribulin mesylateÂ and reduce subsequent doses in patients who experience febrile neutropenia or Grade 4 neutropenia lasting longer than 7 days <content styleCode="italics">[</content>
                           <content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_2_Dose_Modification">Dosage and Administration (2.2)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>. Clinical studies ofÂ eribulin mesylateÂ did not include patients with baseline neutrophil counts below 1,500/mm<sup>3</sup>.</paragraph>
                     </text>
                     <effectiveTime value="20250310"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_2_Peripheral_Neuropathy">
                     <id root="28413f63-ac06-424a-8697-8b969e0e27bb"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.2 </content>
                        <content styleCode="bold">Peripheral </content>
                        <content styleCode="bold">Neuropathy </content>
                     </title>
                     <text>
                        <paragraph>In Study 1, Grade 3 peripheral neuropathy occurred in 8% (40/503) of patients, and Grade 4 in 0.4% (2/503) of patients with metastatic breast cancer (MBC). Peripheral neuropathy was the most common toxicity leading to discontinuation ofÂ eribulin mesylateÂ (5% of patients; 24/503) in Study 1. Â Neuropathy lasting more than one year occurred in 5% (26/503) of patients. Twenty-two percent (109/503) of patients developed a new or worsening neuropathy that had not recovered within a median follow-up duration of 269 days (range 25-662 days).</paragraph>
                        <paragraph>In Study 2, Grade 3 peripheral neuropathy occurred in 3.1% (7/223) of eribulin mesylate-treated patients. Peripheral neuropathy led to discontinuation ofÂ eribulin mesylate in 0.9% of patients. The median time to first occurrence of peripheral neuropathy of any severity was 5 months (range: 3.5 months to 9 months). Â Neuropathy lasting more than 60 days occurred in 58% (38/65) of patients. Â Sixty three percent (41/65) had not recovered within a median follow-up duration of 6.4 months (range: 27 days to 29 months).</paragraph>
                        <paragraph>Monitor patients closely for signs of peripheral motor and sensory neuropathy. WithholdÂ eribulin mesylate in patients who experience Grade 3 or 4 peripheral neuropathy,Â until resolution to Grade 2 or lessÂ <content styleCode="italics">[</content>
                           <content styleCode="italics">seeÂ </content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_2_Dose_Modification">Dosage and Administration (2.2)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_3_Embryo_Fetal_Toxicity">
                     <id root="96305adc-f417-4638-b420-49135a491a2b"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.3 </content>
                        <content styleCode="bold">Embryo</content>
                        <content styleCode="bold">-</content>
                        <content styleCode="bold">Fetal Toxicity</content>
                     </title>
                     <text>
                        <paragraph>Based on findings from an animal reproduction study and its mechanism of action,Â eribulin mesylate can cause fetal harm when administered to a pregnant woman. Â There are no adequate and well-controlled studies ofÂ eribulin mesylate in pregnant women. In animal reproduction studies, eribulin mesylate caused embryo-fetal toxicity when administered to pregnant rats during organogenesis at doses below the recommended human dose. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment withÂ eribulin mesylate and for at least 2 weeks following the final dose. Â Advise males with female partners of reproductive potential to use effective contraception during treatment withÂ eribulin mesylate and for 3.5 months following the final doseÂ <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_1__Pregnancy">Use in Specific Populations (8.1)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_4_QT_Prolongation">
                     <id root="8673dcf4-40ab-4b3c-b167-c3f6dea6ea9e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.4 </content>
                        <content styleCode="bold">QT Prolongation</content>
                     </title>
                     <text>
                        <paragraph>In an uncontrolled open-label ECG study in 26 patients, QT prolongation was observed on Day 8, independent of eribulin concentration, with no QT prolongation observed on Day 1. ECG monitoring is recommended if therapy is initiated in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics, and electrolyte abnormalities. Correct hypokalemia or hypomagnesemia prior to initiating eribulin mesylate and monitor these electrolytes periodically during therapy. Avoid eribulin mesylate in patients with congenital long QT syndrome.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="e7d06d34-71f0-4007-8cfa-13885729b4c2"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6  </content>
                  <content styleCode="bold">ADVERSE REACTIONS</content>
               </title>
               <text/>
               <effectiveTime value="20250312"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (â¥25%) in metastatic breast cancerÂ were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation. (<linkHtml href="#_6_1__Clinical">6.1</linkHtml>)</paragraph>
                        <paragraph>The most common adverse reactions (â¥25%) in liposarcoma and leiomyosarcomaÂ wereÂ fatigue, nausea, alopecia,Â constipation, peripheral neuropathy,Â abdominal pain, and pyrexia.Â Â The most common (â¥5%) Grade 3-4 laboratory abnormalities in liposarcoma and leiomyosarcoma were neutropenia, hypokalemia, and hypocalcemia.Â (<linkHtml href="#_6_1__Clinical">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact the WhiteOak Group, LLC at 1-202-316-0138Â or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_6_1__Clinical">
                     <id root="2c412345-ade3-4c8e-b54d-86bd8cc60be6"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90374-0" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.1 </content>
                        <content styleCode="bold">Clinical Trials Experience</content>
                     </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.</paragraph>
                        <paragraph>The following adverse reactions are discussed in detail in other sections of the labeling:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Neutropenia <content styleCode="italics">[</content>
                              <content styleCode="italics">see </content>
                              <content styleCode="italics">
                                 <linkHtml href="#_5_1_Neutropenia">Warnings and Precautions (5.1)</linkHtml>
                              </content>
                              <content styleCode="italics">]</content>
                           </item>
                           <item>Peripheral neuropathy <content styleCode="italics">[see </content>
                              <content styleCode="italics">
                                 <linkHtml href="#_5_2_Peripheral_Neuropathy">Warnings and Precautions (5.2)]</linkHtml>
                              </content>
                           </item>
                           <item>QT prolongation <content styleCode="italics">[see </content>
                              <content styleCode="italics">
                                 <linkHtml href="#_5_4_QT_Prolongation">Warnings and Precautions (5.4)</linkHtml>
                              </content>
                              <content styleCode="italics">]</content>
                           </item>
                        </list>
                        <paragraph>In clinical trials,Â eribulin mesylate has been administered to 1963 patientsÂ including 467Â patients exposed toÂ eribulin mesylate for 6 months or longer. The majority of the 1963 patients were women (92%) with a median age of 55Â years (range: 17 to 85 years). The racial and ethnic distribution was WhiteÂ (72%), Black (4%), Asian (9%), and other (3%).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Metastatic Breast Cancer</content>
                        </paragraph>
                        <paragraph>The most common adverse reactions (â¥25%) reported in patients receivingÂ eribulin mesylate were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation. The most common serious adverse reactions reported in patients receivingÂ eribulin mesylate were febrile neutropenia (4%) and neutropenia (2%). The most common adverse reaction resulting in discontinuation ofÂ eribulin mesylate was peripheral neuropathy (5%).</paragraph>
                        <paragraph>The adverse reactions described in Table 2 were identified in 750 patients treated in Study 1 <content styleCode="italics">[</content>
                           <content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_14_1_Metastatic_Breast">Clinical Studies (14.1)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>. In Study 1, patients were randomized (2:1) to receive eitherÂ eribulin mesylate (1.4Â mg/m<sup>2</sup>on Days 1 and 8 of a 21-day cycle) or single agent treatment chosen by theirÂ physicianÂ (control group). A total of 503 patients receivedÂ eribulin mesylate and 247 patients in the control group received therapy consisting of chemotherapy [total 97% (anthracyclines 10%, capecitabine 18%, gemcitabine 19%, taxanes 15%, vinorelbine 25%, other chemotherapies 10%)] or hormonal therapy (3%). The median duration of exposure was 118 days for patients receivingÂ eribulin mesylate and 63 days for patients receiving control therapy. Table 2 reports the most common adverse reactions occurring in at least 10% of patients in either group.</paragraph>
                        <table>
                           <caption>Table 2: Adverse Reactions<sup>a</sup> with a Per-Patient Incidence of at Least 10% in StudyÂ 1</caption>
                           <colgroup>
                              <col width="238"/>
                              <col width="82"/>
                              <col width="76"/>
                              <col width="92"/>
                              <col width="85"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" align="left">
                                    <br/>
                                    <br/>
                                    <content styleCode="bold">Adverse Reactions</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Eribulin Mesylate</content>
                                    <br/>
                                    <content styleCode="bold">n=503</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Control Group</content>
                                    <br/>
                                    <content styleCode="bold">n=247</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule"/>
                                 <td styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">All Grades</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">â¥ Grade 3</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">All Grades</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">â¥ Grade 3</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5">
                                    <content styleCode="bold">Blood and </content>
                                    <content styleCode="bold">l</content>
                                    <content styleCode="bold">ymphatic </content>
                                    <content styleCode="bold">s</content>
                                    <content styleCode="bold">ystem </content>
                                    <content styleCode="bold">d</content>
                                    <content styleCode="bold">isorders</content>
                                    <sup>b</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Neutropenia</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">82%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">57%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">53%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">23%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Anemia</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">58%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">2%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">55%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">4%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5">
                                    <content styleCode="bold">Nervous system disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Peripheral neuropathy<sup>c</sup>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">35%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">8%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">16%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">2%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Headache</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">19%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">&lt;1%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">12%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">&lt;1%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5">
                                    <content styleCode="bold">General disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Asthenia/Fatigue</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">54%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">10%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">40%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">11%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Pyrexia</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">21%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">&lt;1%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">13%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">&lt;1%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Mucosal inflammation</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">9%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">10%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">2%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Nausea</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">35%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">28%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">3%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Constipation</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">25%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">21%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Vomiting</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">18%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">18%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Diarrhea</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">18%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">18%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5">
                                    <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Arthralgia/Myalgia</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">22%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">&lt;1%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">12%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Back pain</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">16%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">7%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">2%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Bone pain</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">12%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">2%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">9%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">2%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Pain in extremity</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">11%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">10%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5">
                                    <content styleCode="bold">Metabolism and nutrition disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Decreased weight</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">21%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">14%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">&lt;1%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Anorexia</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">20%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">13%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5">
                                    <content styleCode="bold">Respiratory, thoracic, and mediastinal disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Dyspnea</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">16%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">4%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">13%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">4%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Cough</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">14%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">0</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">9%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5">
                                    <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Alopecia</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">45%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">NA<sup>d</sup>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">10%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">NA<sup>d</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5">
                                    <content styleCode="bold">Infections</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Urinary Tract Infection</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">10%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">5%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5" align="left">
                                    <sup>a</sup>adverse reactions were graded per National Cancer Institute Criteria for Adverse Events version 4.0.Â <br/>
                                    <sup>b</sup>based upon laboratory data.<br/>
                                    <sup>c</sup>includes peripheral neuropathy, peripheral sensorimotor neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensory neuropathy, and paraesthesia.<br/>
                                    <sup>d</sup>not applicable; (grading system does not specify &gt;Â Grade 2 for alopecia).</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Cytopenias</content>: Grade 3 neutropenia occurred in 28% (143/503) of patients who receivedÂ eribulin mesylate in Study 1, and 29% (144/503) of patients experienced Grade 4 neutropenia. Febrile neutropenia occurred in 5% (23/503) of patients; two patients (0.4%) died from complications of febrile neutropenia. Dose reduction due to neutropenia was required in 12% (62/503) of patients and discontinuation was required in &lt;1% of patients. Â The mean time to nadir was 13 days and the mean time to recovery from severe neutropenia (&lt;500/mm<sup>3</sup>) was 8 days. Â Grade 3 or greater thrombocytopenia occurred in 1% (7/503) of patients.Â Â G-CSF (granulocyte colony-stimulating factor) or GM-CSF (granulocyteâmacrophage colony-stimulating factor) was used in 19% of patients who received eribulin mesylate. Â </paragraph>
                        <paragraph>
                           <content styleCode="underline">Peripheral </content>
                           <content styleCode="underline">Neuropathy</content>:Â Â In Study 1, 17% of enrolled patients had Grade 1 peripheral neuropathy and 3% of patients had GradeÂ 2 peripheral neuropathy at baseline. Dose reduction due to peripheral neuropathy was required by 3% (14/503) of patients who received eribulin mesylate. Four percent (20/503) of patients experienced peripheral motor neuropathy of any grade and 2% (8/503) of patients developed Grade 3 peripheral motor neuropathy.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Liver Function Test Abnormalities</content>:Â  Among patients with Grade 0 or 1 ALT levels at baseline, 18% of eribulin mesylate-treated patients experienced Grade 2 or greater ALT elevation. One eribulin mesylate-treated patient without documented liver metastases had concomitant Grade 2 elevations in bilirubin and ALT; these abnormalities resolved and did not recurÂ withÂ re-exposure to eribulin mesylate.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Less Common Adverse Reactions</content>: The following additional adverse reactions were reported in â¥5% to &lt;10% of the eribulin mesylate-treated group:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Eye Disorders:</content>Â Â increased lacrimation</item>
                           <item>
                              <content styleCode="bold">Gastrointestinal Disorders:</content>Â Â dyspepsia, abdominal pain, stomatitis, dry mouth</item>
                           <item>
                              <content styleCode="bold">General Disorders and Administration Site Conditions:</content> peripheral edema</item>
                           <item>
                              <content styleCode="bold">Infections and Infestations:</content>Â Â upper respiratory tract infection</item>
                           <item>
                              <content styleCode="bold">Metabolism and Nutrition Disorders:</content>Â Â hypokalemia</item>
                           <item>
                              <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders:</content>muscle spasms, muscular weakness</item>
                           <item>
                              <content styleCode="bold">Nervous System Disorders:</content>Â Â dysgeusia, dizziness</item>
                           <item>
                              <content styleCode="bold">Psychiatric Disorders:</content>Â Â insomnia, depression</item>
                           <item>
                              <content styleCode="bold">Skin and Subcutaneous Tissue Disorders:</content>Â Â rash</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">Liposarcoma</content>
                        </paragraph>
                        <paragraph>The safety ofÂ eribulin mesylate was evaluated in Study 2, anÂ open-label, randomized, multicenter, active-controlled trial, in which patients were randomized (1:1) to receive eitherÂ eribulin mesylate 1.4Â mg/m<sup>2 </sup>on Days 1 and 8 of a 21-day cycle or dacarbazineÂ at doses of 850Â mg/m<sup>2</sup> (20%), 1000Â mg/m<sup>2</sup> (64%), or 1200Â mg/m<sup>2</sup> (16%)Â every 3 weeks.Â Â A total of Â 223 patients receivedÂ eribulin mesylate and 221 patients received dacarbazine. Patients were required to have received at least two prior systemic chemotherapy regimens. Â The trial excluded patients with pre-existing â¥Â Grade 3 peripheral neuropathy, known central nervous system metastasis, elevated serum bilirubin or significant chronic liver disease, history of myocardial infarction within 6 months, history of New York Heart Association Class II or IV heart failure, or cardiac arrhythmia requiring treatment. The median age of the safety population in Study 2 was 56 years (range: 24 to 83 years); 67% female; 73% White, 3% Black or African American, 8% Asian/Pacific Islander, and 15% unknown; 99% received prior anthracycline-containing regimen; and 99% received â¥Â 2 prior regimens. The median duration of exposure was 2.3 monthsÂ (range: 21 days to 26 months)Â for patients receivingÂ eribulin mesylateÂ <content styleCode="italics">[</content>
                           <content styleCode="italics">see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_14_2_Liposarcoma">Clinical Studies (14.2)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>The most common adverse reactions (â¥25%) reported in patients receivingÂ eribulin mesylate were fatigue,Â nausea, alopecia, constipation, peripheral neuropathy,Â abdominal pain, and pyrexia. Â The most common (â¥5%) Grade 3-4 laboratory abnormalities reported in patients receivingÂ eribulin mesylate were neutropenia, hypokalemia, and hypocalcemia. The most common serious adverse reactions reported in patients receivingÂ eribulin mesylate were neutropenia (4.9%) and pyrexia (4.5%). Permanent discontinuation ofÂ eribulin mesylate for adverse reactions occurred in 8% of patients. The most common adverse reactions resulting in discontinuation ofÂ eribulin mesylate were fatigue and thrombocytopenia (0.9% each).Â Â Twenty-six percent of patients required at least one dose reduction. The most frequent adverse reactions that led to dose reduction were neutropenia (18%) and peripheral neuropathy (4.0%).</paragraph>
                        <paragraph>Table 3Â summarizesÂ the incidence of adverse reactions occurring in at least 10% of patients inÂ the eribulin mesylate-treated arm in Study 2.</paragraph>
                        <table>
                           <caption>Table 3: Adverse Reactions<sup>a</sup> Occurring in â¥10% (all Grades) of Patients Treated on the Eribulin Mesylate arm and at a Higher Incidence than in the Dacarbazine Arm (Between Arm Difference of â¥5% for All Grades or â¥2% for Grades 3 and 4) (Study 2)<sup>b</sup>
                           </caption>
                           <colgroup>
                              <col width="229"/>
                              <col width="101"/>
                              <col width="78"/>
                              <col width="90"/>
                              <col width="78"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" align="center">
                                    <br/>
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Eribulin Mesylate</content>
                                    <br/>
                                    <content styleCode="bold">n</content>
                                    <content styleCode="bold">=22</content>
                                    <content styleCode="bold">3</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Dacarbazine</content>
                                    <br/>
                                    <content styleCode="bold">n</content>
                                    <content styleCode="bold">=22</content>
                                    <content styleCode="bold">1</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="bottom"/>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">
                                    <content styleCode="bold">All Grades</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">
                                    <content styleCode="bold">Grades 3-4</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">
                                    <content styleCode="bold">All Grades</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">
                                    <content styleCode="bold">Grades 3-4</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5" valign="bottom">
                                    <content styleCode="bold">Nervous </content>
                                    <content styleCode="bold">s</content>
                                    <content styleCode="bold">ystem </content>
                                    <content styleCode="bold">d</content>
                                    <content styleCode="bold">isorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="bottom">Peripheral Neuropathy<sup>c</sup>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">29%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">3.1%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">8%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">0.5%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="bottom">Headache</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">18%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">0%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">10%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">0%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5" valign="bottom">
                                    <content styleCode="bold">General </content>
                                    <content styleCode="bold">d</content>
                                    <content styleCode="bold">isorders </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="bottom">Pyrexia</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">28%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">0.9%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">14%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">0.5%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5" valign="bottom">
                                    <content styleCode="bold">G</content>
                                    <content styleCode="bold">astrointestinal</content>
                                    <content styleCode="bold">d</content>
                                    <content styleCode="bold">isorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="bottom">Constipation</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">32%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">0.9%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">26%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">0.5%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="bottom">Abdominal pain<sup>d</sup>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">29%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">1.8%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">23%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">4.1%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="bottom">Stomatitis</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">14%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">0.9%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">5%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">0.5%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5" valign="bottom">
                                    <content styleCode="bold">Skin and </content>
                                    <content styleCode="bold">s</content>
                                    <content styleCode="bold">ubcutaneous </content>
                                    <content styleCode="bold">t</content>
                                    <content styleCode="bold">issue </content>
                                    <content styleCode="bold">d</content>
                                    <content styleCode="bold">isorders</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="bottom">Alopecia</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">35%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">NA<sup>e</sup>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">2.7%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">NA<sup>e</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5" valign="bottom">
                                    <content styleCode="bold">Infections</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="bottom">Urinary tract infection</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">11%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">2.2%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">5%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center" valign="bottom">0.5%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5" valign="bottom">
                                    <sup>a</sup>Â Adverse reactions were graded per National Cancer Institute Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03).<br/>
                                    <sup>b</sup>Â Safety data from one study site enrolling six patients were excluded.<br/>
                                    <sup>c</sup>Includes peripheral neuropathy, peripheral sensorimotor neuropathy, peripheral motor neuropathy, polyneuropathy, peripheral sensory neuropathy, and paraesthesia.<br/>
                                    <sup>d</sup>Â Includes abdominal pain, upper abdominal pain, lower abdominal pain, abdominal discomfort.<br/>
                                    <sup>e</sup>Â Not applicable; (grading system does not specify &gt;Â Grade 2 for alopecia).</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>OtherÂ clinically important adverse reactions occurring in â¥10% of the eribulin mesylate-treated patients were:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Gastrointestinal Disorders:</content> nausea (41%); vomiting (19%), diarrhea (17%)</item>
                           <item>
                              <content styleCode="bold">General Disorders:</content>Â Â asthenia/fatigue (62%); peripheral edema (12%)</item>
                           <item>
                              <content styleCode="bold">Metabolism and Nutrition Disorders: </content> decreased appetite (19%)</item>
                           <item>
                              <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders:Â </content>arthralgia/myalgia (16%); back pain (16%)</item>
                           <item>
                              <content styleCode="bold">Respiratory Disorders:Â </content>cough (18%)</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Less Common Adverse Reactions</content>: The following additional clinically important adverse reactions were reported in â¥5% to &lt;10% of the eribulin mesylate-treated group:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Blood and Lymphatic System Disorders:</content> thrombocytopenia</item>
                           <item>
                              <content styleCode="bold">Eye Disorders:</content> increased lacrimation</item>
                           <item>
                              <content styleCode="bold">Gastrointestinal Disorders:</content> dyspepsia</item>
                           <item>
                              <content styleCode="bold">Metabolism and Nutrition Disorders:</content> hyperglycemia</item>
                           <item>
                              <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders:</content> muscle spasms, musculoskeletal pain</item>
                           <item>
                              <content styleCode="bold">Nervous System Disorders:</content> dizziness, dysgeusia</item>
                           <item>
                              <content styleCode="bold">Psychiatric Disorders:</content> insomnia, anxiety</item>
                           <item>
                              <content styleCode="bold">Respiratory, Thoracic, and Mediastinal Disorders:</content> oropharyngeal pain</item>
                           <item>
                              <content styleCode="bold">Vascular Disorders:</content> hypotension</item>
                        </list>
                        <table>
                           <caption>Table 4: Laboratory Abnormalities Occurring in â¥10% (all Grades) of Patients Treated on the Eribulin Mesylate arm and at a Higher Incidence than in the Dacarbazine Arm (Between Arm Difference of â¥5% forÂ All Grades or â¥2% for Grades 3 and 4)<sup>a</sup> (Study 2)<sup>â </sup>
                           </caption>
                           <colgroup>
                              <col width="261"/>
                              <col width="109"/>
                              <col width="108"/>
                              <col width="108"/>
                              <col width="111"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Laboratory Abnormality</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Eribulin Mesylate</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Dacarbazine</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule"/>
                                 <td styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">All Grades</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Grades 3 - 4</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">All Grades</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Grades 3 </content>
                                    <content styleCode="bold">â</content>
                                    <content styleCode="bold"> 4</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5" valign="bottom">
                                    <content styleCode="bold">Hematology</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="bottom">Anemia</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">70%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">4.1%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">52%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">6%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="bottom">Neutropenia</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">63%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">32%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">30%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">8.9%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5">
                                    <content styleCode="bold">Chemistry</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Increased alanine aminotransferase (ALT)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">43%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">2.3%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">28%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">2.3%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Increased aspartate aminotransferase (AST)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">36%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">0.9%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">16%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">0.5%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Hypokalemia</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">30%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">5.4%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">14%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">2.8%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Hypocalcemia</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">28%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">5%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">18%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1.4%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Hypophosphatemia</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">20%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">3.2%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">11%</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1.4%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="5">
                                    <sup>a</sup>Each test incidence is based on the number of patients who had both baselineÂ and at least one on-study measurement and at least 1 grade increase from baseline.Â Eribulin Mesylate group (range 221-222) and dacarbazine group (range 214-215).<br/>
                                    <content styleCode="bold">
                                       <sup>â </sup>
                                    </content>Laboratory results were graded per NCI CTCAE v4.03.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="e754f39d-dc33-411a-a687-1dafa2c5c021"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90375-7" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.</content>
                        <content styleCode="bold">2Â </content>
                        <content styleCode="bold">Post</content>
                        <content styleCode="bold">ma</content>
                        <content styleCode="bold">rketing Experience</content>
                     </title>
                     <text>
                        <paragraph>The following adverse drug reactionsÂ haveÂ been identified during post-approval of eribulin mesylate. Â Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Blood and Lymphatic System Disorders: </content>lymphopenia</item>
                           <item>
                              <content styleCode="bold">Gastrointestinal Disorders:</content>Â Â pancreatitis</item>
                           <item>
                              <content styleCode="bold">Hepatobiliary Disorders: </content>hepatotoxicity</item>
                           <item>
                              <content styleCode="bold">Immune System Disorders:</content>Â Â drug hypersensitivity</item>
                           <item>
                              <content styleCode="bold">Infections and Infestations:</content>Â Â pneumonia, sepsis/neutropenic sepsis</item>
                           <item>
                              <content styleCode="bold">Metabolism and Nutrition Disorders:</content>Â Â hypomagnesemia, dehydration</item>
                           <item>
                              <content styleCode="bold">Respiratory, thoracic and mediastinal disorders:</content>Â Â interstitial lung disease</item>
                           <item>
                              <content styleCode="bold">Skin and Subcutaneous Tissue Disorders:</content>Â Â pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis</item>
                        </list>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="5bd09f95-959c-44a7-b2ab-281142941509"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">7 </content>
                  <content styleCode="bold">DRUG INTERACTIONS</content>
               </title>
               <effectiveTime value="20250312"/>
               <component>
                  <section>
                     <id root="b84075c1-3dbd-4e2e-b18b-ddd1ee283657"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.1 </content>
                        <content styleCode="bold">Effects of Other Drugs on Eribulin Mesylate</content>
                     </title>
                     <text>
                        <paragraph>No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducersÂ orÂ P-glycoprotein (P-gp) inhibitors. Clinically meaningful differences in exposure (AUC) were not observed in patients with advanced solid tumors whenÂ eribulin mesylate was administered with or without ketoconazole (a strong inhibitor of CYP3A4 and a P-gp inhibitor) and whenÂ eribulin mesylate was administered with or without rifampin (a CYP3A4 inducer) <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">Clinical Pharmacology (12.3)</linkHtml>
                           </content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="4123e314-5f31-4f30-8487-7d182a7a080a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.2 </content>
                        <content styleCode="bold">Effect</content>
                        <content styleCode="bold">s</content>
                        <content styleCode="bold"> of Eribulin Mesylate on Other Drugs</content>
                     </title>
                     <text>
                        <paragraph>Eribulin does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4 enzymes or induce CYP1A2, CYP2C9, CYP2C19 or CYP3A4 enzymes at relevant clinical concentrations. Eribulin is not expected to alter the plasma concentrations of drugs that are substrates of these enzymes <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">Clinical Pharmacology (12.3)</linkHtml>
                           </content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="bd4500e0-6f37-4fd4-b06e-bdd3b38114d0"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8 </content>
                  <content styleCode="bold">USE IN SPECIFIC POPULATIONS</content>
               </title>
               <effectiveTime value="20250312"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Lactation: Â Do not breastfeed. (<linkHtml href="#_8_2__">8.2</linkHtml>)<br/>
                           </item>
                           <item>Hepatic Impairment: Â A lower starting dose is recommended for patients with mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment.  Patients with severe hepatic impairment (Child-Pugh C) were not studied. (<linkHtml href="#_8_6_Hepatic_Impairment">8.6</linkHtml>)<br/>
                           </item>
                           <item>Renal Impairment:  A lower starting dose is recommended for patients with moderate (CLcr 30-49 mL/min) or severe (CLcr 15-29 mL/min) renal impairment. (<linkHtml href="#_8_7_Renal_Impairment">8.7</linkHtml>)  </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_8_1__Pregnancy">
                     <id root="27eb2e58-a9fa-4195-ace3-589604e88687"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1 </content>
                        <content styleCode="bold">Pregnancy </content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>Based on findings from an animal reproduction study and its mechanism of action,Â eribulin mesylate can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_1_Mechanism_of">Clinical Pharmacology (12.1)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>. There are no available data on the use ofÂ eribulin mesylate during pregnancy. In an animal reproduction study, eribulin mesylate caused embryo-fetal toxicity when administered to pregnant rats during organogenesis at doses below the recommended human dose <content styleCode="italics">[see Data]</content>.Â  Advise pregnant women of the potential risk to a fetus.</paragraph>
                        <paragraph>The estimated background risks of major birth defects and miscarriage for the indicated populations are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically-recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data </content>
                        </paragraph>
                        <paragraph>In an embryo-fetal developmental toxicity study, pregnant rats received intravenous infusion of eribulin mesylate during organogenesis (Gestation Days 8, 10, and 12) at doses approximately 0.04, 0.13, 0.43 and 0.64 times the recommended human dose, based on body surface area. Increased abortion and severe fetal external or soft tissue malformations, including the absence of a lower jaw and tongue, or stomach and spleen, were observed at doses 0.64 times the recommended human dose of 1.4 mg/m<sup>2</sup> based on body surface area. Increased embryo-fetal death/resorption, reduced fetal weights, and minor skeletal anomalies consistent with developmental delay were also reported at doses at or aboveÂ a maternally toxic dose of approximately 0.43 times the recommended human dose.</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_2__">
                     <id root="87e1121b-3eca-4877-bb8c-c5d28fb74d3e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77290-5" displayName="LACTATION SECTION"/>
                     <title>
                        <content styleCode="bold">8.2 </content>
                        <content styleCode="bold">Lactation </content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary </content>
                        </paragraph>
                        <paragraph>There is no information regarding the presence of eribulin mesylate or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. No lactation studies in animals were conducted.Â Â Because of the potential for serious adverse reactions in breastfed infants from eribulin mesylate,Â advise women not to breastfeed during treatment withÂ eribulin mesylate and for 2 weeks after the final dose.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_3_Females_and">
                     <id root="c7a1e7f2-52d6-40ba-8d99-219e8a7d2d11"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77291-3" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>
                        <content styleCode="bold">8.3 </content>
                        <content styleCode="bold">Females and Males of Reproductive Potential </content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Contraception </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females</content>
                        </paragraph>
                        <paragraph>Based on findings from an animal reproduction study andÂ its mechanism of action,Â eribulin mesylate can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_1__Pregnancy">Use in Specific Populations (8.1)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>. Â Advise females of reproductive potential to use effective contraception during treatment withÂ eribulin mesylate and for at least 2 weeks following the final dose<content styleCode="bold">. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Based on its mechanism of action, advise males with female partners of reproductive potential to use effective contraception during treatment withÂ eribulin mesylate and for 3.5 monthsÂ followingÂ the final dose.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Based on animal data,Â eribulin mesylate may result in damage to male reproductive tissues leading to impaired fertility of unknown duration <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_13_1_Carcinogenesis__Mutagenesis_">Nonclinical Toxicology (13.1)</linkHtml>
                           </content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7275d6d7-0020-4e29-84e4-c10600f3254e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4 </content>
                        <content styleCode="bold">Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>The safety and effectiveness ofÂ eribulin mesylate in pediatric patients have not been established.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information describing clinical studies in which efficacy was not demonstrated is approved for Eisai Incâs HALAVEN<sup>Â®</sup> (eribulin mesylate) injection. However, due to Eisai Incâs marketing exclusivity rights, this drug product is not labeled with that information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="66daaf31-33ab-4eec-b8fa-f054eba3bd5c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5 </content>
                        <content styleCode="bold">Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>Study 1 did not include sufficient numbers of subjects with metastatic breast cancer aged 65 years and older to determine whetherÂ they respond differently from younger subjects.Â Of the 827 subjects who received the recommended dose and schedule ofÂ eribulin mesylate in clinical studies with advanced breast cancer, 15% (121/827) were 65 and older, and 2% (17/827) patients were 75 and older.Â No overall differences in safety were observed between these subjects and younger subjects.</paragraph>
                        <paragraph>Clinical studies ofÂ eribulin mesylate did not include a sufficient number of subjects in Study 2Â aged 65 years and older to determine whether they respond differently from younger subjects.</paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_6_Hepatic_Impairment">
                     <id root="7b9cc620-92d6-4225-b6d6-2fe504b1d728"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="88829-7" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>
                        <content styleCode="bold">8.6 </content>
                        <content styleCode="bold">Hepatic Impairment</content>
                     </title>
                     <text>
                        <paragraph>Administration ofÂ eribulin mesylate at a dose of 1.1Â mg/m<sup>2</sup> to patients with mild hepatic impairment and 0.7Â mg/m<sup>2</sup> to patients with moderate hepatic impairment resulted in similar exposure to eribulin as a dose of 1.4Â mg/m<sup>2</sup> to patients with normal hepatic function. Therefore, a lower starting dose of 1.1 mg/m<sup>2</sup> is recommended for patients with mild hepatic impairment (Child-Pugh A) and of 0.7 mg/m<sup>2</sup> is recommended for patients with moderate hepatic impairment (Child-Pugh B). Eribulin mesylate was not studied in patients with severe hepatic impairment (Child-Pugh C) <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_1_Recommended_Dose">DosageÂ and Administration (2.1)</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">Clinical Pharmacology (12.3)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>
                           <content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_7_Renal_Impairment">
                     <id root="8b18bd71-bf60-4a4a-8261-fec7a0980c04"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="88828-9" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>
                        <content styleCode="bold">8.7 </content>
                        <content styleCode="bold">Renal Impairment</content>
                     </title>
                     <text>
                        <paragraph>For patients with moderate or severe renal impairment (CLcr 15-49 mL/min), reduce the starting dose toÂ 1.1Â mg/m<sup>2</sup>
                           <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_1_Recommended_Dose">Dosage and Administration (2.1)</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">Clinical Pharmacology (12.3)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>
                           <content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250307"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="ac83096c-f4a1-402a-8dd1-8b9205835ebf"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34088-5" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">10 </content>
                  <content styleCode="bold">OVERDOSAGE</content>
                  <content styleCode="bold"/>
               </title>
               <text>
                  <paragraph>Overdosage ofÂ eribulin mesylate has been reported at approximately 4 times the recommended dose, which resulted in Grade 3 neutropenia lasting seven days and a Grade 3 hypersensitivity reaction lasting one day.</paragraph>
                  <paragraph>There is no known antidote forÂ eribulin mesylate overdose.</paragraph>
               </text>
               <effectiveTime value="20250307"/>
            </section>
         </component>
         <component>
            <section>
               <id root="1af0ee6a-af90-4bba-8b49-60f60c429e94"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11 </content>
                  <content styleCode="bold">DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>Eribulin mesylate injection containsÂ eribulin mesylate,Â a microtubule dynamicsÂ inhibitor. Eribulin mesylate is a synthetic analogue of halichondrin B, a product isolated from the marine spongeÂ <content styleCode="italics">Halichondria okad</content>
                     <content styleCode="italics">ai</content>. The chemical name for eribulin mesylate is 11,15:18,21:24,28-Triepoxy-7,9-ethano-12,15-methano-9<content styleCode="italics">H</content>,15<content styleCode="italics">H</content>-furo[3,2-<content styleCode="italics">i</content>]furo[2',3':5,6]pyrano[4,3-<content styleCode="italics">b</content>][1,4]dioxacyclopentacosin-5(4<content styleCode="italics">H</content>)-one, 2-[(2<content styleCode="italics">S</content>)-3-amino-2-hydroxypropyl]hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)-, (2<content styleCode="italics">R</content>,3<content styleCode="italics">R</content>,3a<content styleCode="italics">S</content>,7<content styleCode="italics">R</content>,8a<content styleCode="italics">S</content>,9<content styleCode="italics">S</content>,10a<content styleCode="italics">R</content>,11<content styleCode="italics">S</content>,12<content styleCode="italics">R</content>,13a<content styleCode="italics">R</content>,13b<content styleCode="italics">S</content>,15<content styleCode="italics">S</content>,18<content styleCode="italics">S</content>,21<content styleCode="italics">S</content>,24<content styleCode="italics">S</content>,26<content styleCode="italics">R</content>,28<content styleCode="italics">R</content>,29a<content styleCode="italics">S</content>)-, methanesulfonate (salt). It has a molecular weight of 826.0 (729.9 for free base). The empirical formula is C<sub>40</sub>H<sub>59</sub>NO<sub>11</sub>â¢CH<sub>4</sub>O<sub>3</sub>S. Eribulin mesylate has the following structural formula:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L50dc4585-6baf-43c7-b502-a201b29e19a2"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>Eribulin mesylate injectionÂ is a clear, colorless, sterile solution for intravenous administration. Each single-dose vial contains 1 mg of eribulin mesylate in 2 mL of solution. Each mL of solution contains 0.5 mg of eribulin mesylate (equivalent to 0.44 mg eribulin) in dehydrated alcohol (5% v/v) and water for injection (95% v/v). Sodium hydroxide orÂ hydrochloric acidÂ may be used for pH adjustment.</paragraph>
               </text>
               <effectiveTime value="20250312"/>
               <component>
                  <observationMedia ID="L50dc4585-6baf-43c7-b502-a201b29e19a2">
                     <text>formula structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Figure 01-formula structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="db22cbd7-122e-4d48-aff3-c88fcfab66fb"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12 </content>
                  <content styleCode="bold">CLINICAL PHARMACOLOGY</content>
               </title>
               <effectiveTime value="20250312"/>
               <component>
                  <section ID="_12_1_Mechanism_of">
                     <id root="5e31bbd0-1f0e-4428-8351-1aa1528067bb"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43679-0" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1 </content>
                        <content styleCode="bold">Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates. Eribulin exerts its effects via a tubulin-based antimitotic mechanism leading to G<sub>2</sub>/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage.</paragraph>
                        <paragraph>In addition, eribulin treatment of human breast cancer cells caused changes in morphology and geneÂ expression as well as decreased migration and invasiveness in vitro. In mouse xenograft models of humanÂ breast cancer, eribulin treatment was associated with increased vascular perfusion and permeability in theÂ tumor cores, resulting in reduced tumor hypoxia, and changes in the expression of genes in tumorÂ specimens associated with a change in phenotype.</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="969e6e19-9868-44e4-9a31-ebfef6a58008"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43681-6" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.2 </content>
                        <content styleCode="bold">Pharmaco</content>
                        <content styleCode="bold">dynamics</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>The effect of eribulin mesylate on the QTc interval was assessed in an open-label, uncontrolled, multicenter, single-arm dedicated QT trial. A total of 26 patients with solid tumors received 1.4 mg/m<sup>2</sup> ofÂ eribulin mesylate on Days 1 and 8 of a 21-day cycle. A delayed QTc prolongation was observed on Day 8, with no prolongation observed on Day 1. Â The maximum mean QTcF change from baseline (95% upper confidence interval) was 11.4 (19.5) ms.</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section ID="_12_3_Pharmacokinetics">
                     <id root="55faa050-7b33-43ee-88d2-1ee2543fcf1a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3 </content>
                        <content styleCode="bold">Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>The pharmacokineticsÂ (PK) of eribulin is linear with a mean elimination half-life of approximately 40 hours, a mean volume of distribution of 43 L/m<sup>2 </sup>to 114 L/m<sup>2</sup>Â and mean clearance of 1.16 L/hr/m<sup>2 </sup>to 2.42 L/hr/m<sup>2 </sup>over the dose range of 0.25 mg/m<sup>2</sup> to 4.0Â mg/m<sup>2</sup>. Â The human plasma protein binding of eribulin at concentrations of 100 ng/mL to 1,000 ng/mL ranges from 49% to 65%. Eribulin exposure after multiple dosing is comparable to that following a single dose. No accumulation of eribulin is observed with weekly administration.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Unchanged eribulin was the major circulating species in plasma following administration of <sup>14</sup>C-eribulin to patients. Metabolite concentrations represented &lt;0.6% of parent compound, confirming that there are no major human metabolites of eribulin.Â Â Cytochrome P450 3A4 (CYP3A4) negligibly metabolizes eribulin <content styleCode="italics">in vitro</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Eribulin is eliminated primarily in feces unchanged. After administration of <sup>14</sup>C-eribulin to patients, approximately 82% of the dose was eliminated in feces and 9% in urine.Â  Unchanged eribulin accounted for approximately 88% and 91% of total eribulin in feces and urine, respectively.Â </paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Age, </content>
                           <content styleCode="italics">Sex</content>
                           <content styleCode="italics">, and Race</content>
                           <content styleCode="italics">/Ethnicity:</content>Â Â Based on a population pharmacokinetic analysis,Â no clinically meaningful differences in the pharmacokineticsÂ of eribulinÂ were observed based on age, sex, or race.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>In a study evaluating the effect of hepatic impairment on the PK of eribulin, eribulin exposures increased by 1.8-fold in patients with mild hepatic impairment (Child-Pugh A; n=7) and by 2.5-fold in patients with moderate (Child-Pugh B; n=5) hepatic impairment as compared to patients with normal hepatic function (n=6). Â Administration ofÂ eribulin mesylate at a dose of 1.1Â mg/m<sup>2</sup> to patients with mild hepatic impairment and 0.7Â mg/m<sup>2</sup> to patients with moderate hepatic impairment resulted in similar exposure to eribulin at a dose of 1.4Â mg/m<sup>2</sup> to patients with normal hepatic function <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_1_Recommended_Dose">Dosage and Administration (2.1)</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_6_Hepatic_Impairment">Use in Specific Populations (8.6)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>
                           <content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal Impairment</content>
                        </paragraph>
                        <paragraph>In a study evaluating the effect of renal impairment on the PK of eribulin, patients with moderate (CLcr 30-49 mL/min; n=7) and severe renal impairment (CLcr 15-29 mL/min; n=6) had 1.5-fold higher eribulin dose-normalized exposures compared to that in patients with normal renal function (CLcr â¥Â 80 mL/min; n=6). Â There were no clinically meaningful changes in patients with mild renal impairment (CLcr 50-79 mL/min; n=27)Â <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_1_Recommended_Dose">Dosage and Administration (2.1)</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_7_Renal_Impairment">Use in Specific Populations (8.7)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>
                           <content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug </content>
                           <content styleCode="underline">Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of </content>
                           <content styleCode="italics">Strong Inhibitors or Inducers of CYP3A4</content>
                           <content styleCode="italics"> on </content>
                           <content styleCode="italics">Eribulin: </content>The effect of a strong CYP3A4 inhibitor and a P-gp inhibitor, ketoconazole, on the PK of eribulin was studied in a crossover trial of 12 patients with advanced solid tumors. No clinically relevant PK interaction was observed whenÂ eribulin mesylate was administered with or without ketoconazole (the geometric mean ratio of the AUC:Â 0.97; 90%Â CI: 0.83, 1.12).</paragraph>
                        <paragraph>The effect of a CYP3A4 inducer, rifampin, on the PK of eribulin was studied in a crossover trial of 14 patients with advanced solid tumors. No clinically relevant PK interaction was observed whenÂ eribulin mesylate was administered with or without rifampin (the geometric mean ratio of the AUC:Â 1.10; 90Â CI%: 0.91, 1.34).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Eribulin on CYP Substrates</content>:Â Â Eribulin shows no induction potential for CYP1A, CYP2B6, CYP2C9, CYP2C19, and CYP3A in primary human hepatocytes. Eribulin inhibits CYP3A4 activity in human liver microsomes, but it is unlikely that eribulin will substantially increase the plasma levels of CYP3A4 substrates. No significant inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP2E1 was detected with eribulin concentrations up to 5Â Î¼M in pooled human liver microsomes. In vitro drug interaction studies indicate that eribulin does not inhibit drugs that are substrates of these enzymes and it is unlikely that eribulin will affect plasma levels of drugs that are substrates of CYP enzymes.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of </content>
                           <content styleCode="italics">Transporters on </content>
                           <content styleCode="italics">Eribulin:</content>In vitro data suggest that eribulin at clinically relevant concentrations is a substrate of P-gp, but is not a substrate of breast cancer resistance protein (BCRP), multidrug resistance proteins (MRP2, MRP4), bile salt extrusion pump (BSEP), organic anion transporting polypeptides (OATP1B1, OATP1B3), organic anion transporters (OAT1, OAT3), organic cation transporters (OCT1, OCT2), or multidrug and toxin extrusion 1 (MATE1).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Eribulin on Transporters:</content>In vitro data suggest that eribulin at clinically relevant concentrations may inhibit P-gp, but does not inhibit BCRP, OATP1B1, OCT1, OAT1, OAT3, or MATE1.</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="91ebdecd-a34a-4ca5-873b-30de8d6a483e"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13 </content>
                  <content styleCode="bold">NONCLINICAL TOXICOLOGY</content>
               </title>
               <effectiveTime value="20250312"/>
               <component>
                  <section ID="_13_1_Carcinogenesis__Mutagenesis_">
                     <id root="8edd2054-9095-40af-94ca-884ca227550c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1 </content>
                        <content styleCode="bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>Carcinogenicity studies have not been conducted with eribulin mesylate.Â Â Eribulin mesylate was not mutagenic in <content styleCode="italics">in vitro</content> bacterial reverse mutation assays (Ames test). Eribulin mesylate was positive in mouse lymphoma mutagenesis assays, and was clastogenic in an <content styleCode="italics">in vivo </content>rat bone marrow micronucleus assay.</paragraph>
                        <paragraph>Fertility studies have not been conducted with eribulin mesylate in humans or animals; however, nonclinical findings in repeat-dose dog and rat toxicology studies suggest that male fertility may be compromised by treatment with eribulin mesylate. Â Rats exhibited testicular toxicity (hypocellularity of seminiferous epithelium with hypospermia/aspermia) following dosing with eribulin mesylate at or above 0.43 timesÂ the recommended human doseÂ (based on body surface area) given once weekly for 3 weeks, or at or above 0.21 times the recommended human dose (based on body surface area) given once weekly for 3 out of 5 weeks, repeated for 6 cycles. Testicular toxicity was also observed in dogs given 0.64 times the recommended human dose (based on body surface area) weekly for 3 out of 5 weeks, repeated for 6 cycles.</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="fa7147a0-61a6-426a-b23f-2efa766c7769"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14 </content>
                  <content styleCode="bold">CLINICAL STUDIES</content>
               </title>
               <effectiveTime value="20250312"/>
               <component>
                  <section ID="_14_1_Metastatic_Breast">
                     <id root="5f4385f7-8086-4eea-b02e-5ade50868eb9"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.1 </content>
                        <content styleCode="bold">Metastatic Breast Cancer</content>
                     </title>
                     <text>
                        <paragraph>Study 1 was an open-label, randomized, multicenter trial of 762 patients with metastatic breast cancer who received at least two chemotherapeutic regimens for the treatment of metastatic disease and experienced disease progression within 6 months of their last chemotherapeutic regimen. Patients were required to receive prior anthracycline- and taxane-based chemotherapy for adjuvant or metastatic disease. Patients were randomized (2:1) to receiveÂ eribulin mesylate (n=508) or a single agent therapyÂ selected prior to randomization (control arm, n=254). Randomization was stratified by geographic region, HER2/<content styleCode="italics">neu</content> status, and prior capecitabine exposure. Eribulin mesylate was administered at a dose of 1.4Â mg/m<sup>2</sup> on Days 1 and 8 of a 21-day cycle. Eribulin mesylate-treated patients received a median of 5 cycles (range:Â 1 to 23 cycles) of therapy. Â Control arm therapy consisted of 97% chemotherapy (26% vinorelbine, 18%Â gemcitabine, 18% capecitabine, 16% taxane, 9% anthracycline, 10% other chemotherapy), and 3% hormonal therapy. The main efficacy outcome was overall survival.</paragraph>
                        <paragraph>Patient demographic and baseline characteristics were comparable between the treatment arms. The median age was 55 (range: 27 to 85 years) and 92% were White. Sixty-four percent of patients were enrolled in North America/Western Europe/Australia, 25% in Eastern Europe/Russia, and 11% in Latin America/South Africa. Â Ninety-one percent of patients had a baseline ECOG performance status of 0 or 1. Tumor prognostic characteristics, including estrogen receptor status (positive: 67%, negative: 28%), progesterone receptor status (positive: 49%, negative: 39%), HER2/<content styleCode="italics">neu</content> receptor status (positive: 16%, negative:Â 74%), triple negative status (ER<sup>-</sup>, PR<sup>-</sup>, HER2/<content styleCode="italics">neu</content>
                           <sup>-</sup>: 19%), presence of visceral disease (82%, including 60% liver and 38% lung) and bone disease (61%), and number of sites of metastases (greater than two: 50%), were also similar in theÂ eribulin mesylate and control arms. Patients received a median of four prior chemotherapy regimens in both arms.</paragraph>
                        <paragraph>In Study 1, a statistically significant improvement in overall survival was observed in patients randomized to the eribulin mesylate arm compared to the control armÂ (see Table 5). An updated, unplanned survival analysis, conducted when 77% of events had been observed (see Figure 1), was consistent with the primary analysis. In patients randomized to eribulin mesylate, the objective response rate by the RECIST criteria was 11% (95% CI: 8.6%, 14.3%) and the median response duration was 4.2Â monthsÂ (95% CI: 3.8, 5.0 months).</paragraph>
                        <table>
                           <caption>Table 5: Comparison of Overall Survival in Eribulin Mesylate and Control ArmÂ -Â Study 1</caption>
                           <colgroup>
                              <col width="209"/>
                              <col width="160"/>
                              <col width="160"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Overall Survival</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Eribulin Mesylate</content>
                                    <br/>
                                    <content styleCode="bold">(n=508)</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Control Arm</content>
                                    <br/>
                                    <content styleCode="bold">(n=254)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="bold">Primary survival analysis</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Number of deaths</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">274</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">148</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Median, months (95% CI)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">13.1 (11.8, 14.3)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">10.6 (9.3, 12.5)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Hazard Ratio (95% CI)<sup>a</sup>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">0.81 (0.66, 0.99)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <content styleCode="italics">P</content> value<sup>b</sup>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">0.041</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="bold">Updated survival analysis</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Number of deaths</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">386</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">203</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Median, months (95% CI)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">13.2 (12.1, 14.4)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">10.6 (9.2, 12.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="3">CI = confidence interval<br/>
                                    <sup>a</sup>Â Based on Cox proportional hazards model stratified by geographic region, HER2 status, and prior capecitabine therapy. <br/>
                                    <sup>b</sup> Based on a log-rank test stratified by geographic region, HER2 status, and prior capecitabine therapy.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph styleCode="MultiMediaCaption"/>
                        <paragraph styleCode="MultiMediaCaption">Figure 1: Updated Overall Survival Analysis forÂ Study 1</paragraph>
                        <paragraph styleCode="MultiMediaCaption">
                           <renderMultiMedia referencedObject="Lc0892fa9-64af-4878-981e-a49d8e849d3c"/>
                        </paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250312"/>
                     <component>
                        <observationMedia ID="Lc0892fa9-64af-4878-981e-a49d8e849d3c">
                           <text>Figure 1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="Fig 1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="_14_2_Liposarcoma">
                     <id root="8e6286c3-d401-4099-af1a-184d3c2978db"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.2Â </content>
                        <content styleCode="bold">Liposarcoma </content>
                     </title>
                     <text>
                        <paragraph>The efficacy and safety ofÂ eribulin mesylate were evaluatedÂ in Study 2, an open-label, randomized (1:1), multicenter, active-controlled trial. Â Eligible patients were required to have unresectable, locally advanced or metastatic liposarcoma or leiomyosarcoma, at least two prior systemic chemotherapies (one of which must have included an anthracycline), and disease progression within 6 months of the most recent chemotherapy regimen. Â Patients were randomized toÂ eribulin mesylate 1.4 mg/m<sup>2</sup>Â administered intravenously on Days 1 and 8 of a 21-day cycle or to dacarbazine at a dose ofÂ 850 mg/m<sup>2</sup>, 1000 mg/m<sup>2</sup>, or 1200 mg/m<sup>2</sup> administered intravenously every 21 daysÂ (dacarbazine dose was selected by the investigator prior to randomization).Â  Treatment continued until disease progression or unacceptable toxicity. Â Randomization was stratified by histology (liposarcoma or leiomyosarcoma), number of prior therapies (2 vs. &gt;Â 2), and geographic region (U.S. and Canada vs. Western Europe, Australia, and Israel vs. Eastern Europe, Latin America, and Asia).Â  The major efficacy outcome measure was overall survival (OS). Additional efficacy outcome measures were progression-free survival (PFS) and confirmed objective response rate (ORR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1).Â Â Patients in the dacarbazine arm were not offeredÂ eribulin mesylate at the time of disease progression.</paragraph>
                        <paragraph>A total of 446 patients were randomized, 225 to theÂ eribulin mesylate arm and 221 to the dacarbazine arm.Â The median age was 56 years (range:Â 24 to 83);Â 33% were male; 73% were White;Â 44% had ECOG performance status (PS) 0 and 53% had ECOG PS 1; 68% had leiomyosarcoma and 32% had liposarcoma; 39% were enrolled in U.S. and CanadaÂ (Region 1) and 46% were enrolled in Western Europe, Australia, and Israel (Region 2); and 47% received more than two prior systemic chemotherapies. Â The most common (&gt;40%) prior systemic chemotherapies were doxorubicin (90%), ifosfamide (62%), gemcitabine (59%), trabectedin (50%), and docetaxel (48%).</paragraph>
                        <paragraph>Of the 143 patients with liposarcoma, the median age was 55 years (range: 32 to 83); 62% were male, 72% were White; 41% had ECOG PS of 0 and 53% had ECOG PS of 1; 35% were enrolled in Region 1Â and 51% were enrolled in Region 2; and 44% received more than two prior systemic chemotherapies. Â The distribution of subtypes of liposarcoma, based on local histologic assessment, were 45% dedifferentiated, 37% myxoid/round cell, and 18% pleomorphic.</paragraph>
                        <paragraph>Study 2 demonstrated a statistically significant improvement in OS in patients randomized toÂ eribulin mesylate compared with dacarbazine (see Table 6). Â There was no significant difference in progression-free survival in the overall population. Treatment effects ofÂ eribulin mesylate were limited to patients with liposarcoma based on pre-planned, exploratoryÂ subgroup analyses of OS and PFS (see Tables 6 and 7 and Figure 2).Â There was no evidence of efficacy ofÂ eribulin mesylate in patients with advanced or metastatic leiomyosarcoma in Study 2 (see Table 7).</paragraph>
                        <table>
                           <caption>Table 6: Efficacy Results for the Liposarcoma Stratum and All Patients* in Study 2<sup>a</sup>
                           </caption>
                           <colgroup>
                              <col width="200"/>
                              <col width="94"/>
                              <col width="2"/>
                              <col width="76"/>
                              <col width="78"/>
                              <col width="105"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule"/>
                                 <td styleCode="Lrule Rrule Toprule" colspan="3" align="center">
                                    <content styleCode="bold">Liposarcoma</content>
                                    <br/>
                                    <content styleCode="bold">Stratum</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">All Patients</content>
                                    <content styleCode="bold">*</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule"/>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Eribulin Mesylate</content>
                                    <br/>
                                    <content styleCode="bold">(n=71)</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Dacarbazine</content>
                                    <br/>
                                    <content styleCode="bold">(n=72)</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Eribulin Mesylate</content>
                                    <br/>
                                    <content styleCode="bold">(n=22</content>
                                    <content styleCode="bold">5</content>
                                    <content styleCode="bold">)</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Dacarbazine</content>
                                    <br/>
                                    <content styleCode="bold">(n=22</content>
                                    <content styleCode="bold">1</content>
                                    <content styleCode="bold">)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="6" valign="bottom">
                                    <content styleCode="bold">Overall </content>
                                    <content styleCode="bold">s</content>
                                    <content styleCode="bold">urvival</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="bottom">Â Â Â Deaths, n (%)</td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">52 (73)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">63 (88)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">173 (77)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">179 (81)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="bottom">Â Â Â Median, months<br/>Â Â Â (95% CI)</td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">15.6<br/>(10.2, 18.6)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">8.4<br/>(5.2, 10.1)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">13.5<br/>(11.1, 16.5)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">11.3<br/>(9.5, 12.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="bottom">Â Â Â Hazard ratio (HR)<br/>Â Â Â (95% CI)</td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="3" align="center">0.51 <br/>(0.35, 0.75)</td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">0.75 <br/>(0.61, 0.94)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Stratified log-rank p value</td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="3" align="center">N/A<sup>â </sup>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">0.011</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="6">
                                    <content styleCode="bold">Progression-free survival</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="bottom">Â Â Â Events, n (%)</td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">57 (80)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">59 (82)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">194 (86)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">185 (84)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="bottom">Â Â Â Â Â Â Disease progression</td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">53</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">52</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">180</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">170</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="bottom">Â Â Â Â Â Â Death</td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">4</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">7</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">14</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">15</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="bottom">Â Â Â Median, months<br/>Â Â Â (95% CI)</td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">2.9<br/> (2.6, 4.8)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1.7 <br/>(1.4, 2.6)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">2.6 <br/>(2.0, 2.8)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">2.6 <br/>(1.7, 2.7)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â HR<br/>Â Â Â (95% CI)</td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="3" align="center">0.52Â <br/>(0.35, 0.78)</td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">0.86Â <br/>(0.69, 1.06)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="6">
                                    <content styleCode="bold">Objective </content>
                                    <content styleCode="bold">response rate</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" valign="bottom">Â Â Â Objective response rate (%)<br/>Â Â Â (95% CI)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1.4Â <br/>(0, 7.6)</td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">0Â <br/>(0, 4.2)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">4.0Â <br/>(1.8, 7.5)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">5.0 <br/>(2.5, 8.7)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a</sup>Â Efficacy data from one study site enrolling six patients were excluded. <br/>*All patients = liposarcoma and leiomyosarcoma.<br/>
                           <sup>â </sup>N/A = not applicable</paragraph>
                        <paragraph styleCode="MultiMediaCaption"/>
                        <paragraph styleCode="MultiMediaCaption">Figure 2: Kaplan-Meier Curves of Overall Survival in the Liposarcoma Stratum inÂ Study 2</paragraph>
                        <paragraph styleCode="MultiMediaCaption">
                           <renderMultiMedia referencedObject="Lf2bf71aa-d0f4-445e-81cb-187135b86d09"/>
                        </paragraph>
                        <table>
                           <caption>Table 7: Efficacy Results for the Leiomyosarcoma Stratum inÂ Study 2<sup>a</sup>
                           </caption>
                           <colgroup>
                              <col width="210"/>
                              <col width="132"/>
                              <col width="150"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" align="center"/>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Leiomyosarcoma</content>
                                    <br/>
                                    <content styleCode="bold">Stratum</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="center"/>
                                 <td styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Eribulin Mesylate</content>
                                    <br/>
                                    <content styleCode="bold">(n=15</content>
                                    <content styleCode="bold">4</content>
                                    <content styleCode="bold">)</content>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">
                                    <content styleCode="bold">Dacarbazine</content>
                                    <br/>
                                    <content styleCode="bold">(n=1</content>
                                    <content styleCode="bold">49</content>
                                    <content styleCode="bold">)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="bold">Overall </content>
                                    <content styleCode="bold">s</content>
                                    <content styleCode="bold">urvival</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Deaths, n (%)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">121 (79)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">116 (78)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Median, monthsÂ Â Â <br/>Â Â Â (95% CI)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">12.8<br/>(10.3, 14.8)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">12.3<br/>(11.0, 15.1)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â HR (95% CI)</td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">0.90 (0.69, 1.18)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="3">
                                    <content styleCode="bold">Progression-free survival</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Events, n (%)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">137 (89)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">126 (85)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Â Â Disease progression</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">127</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">118</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Â Â Death</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">10</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Median, months<br/>Â Â Â (95% CI)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">2.2 <br/>(1.5, 2.7)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">2.6 <br/>(2.2, 2.9)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â HR (95% CI)</td>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">1.05 (0.81, 1.35)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Â Â Â Objective response rate (%)<br/>Â Â Â (95% CI)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">5.2<br/> (2.3, 10)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">7.4<br/>(3.7, 12.8)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a</sup> Efficacy data from one study site enrolling six patients were excluded.</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                     <component>
                        <observationMedia ID="Lf2bf71aa-d0f4-445e-81cb-187135b86d09">
                           <text>Figure 2</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="Fig 2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="6b0be496-6b58-49f6-9abc-48df8fb2a8a9"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34093-5" displayName="REFERENCES SECTION"/>
               <title>
                  <content styleCode="bold">15Â </content>
                  <content styleCode="bold">REFERENCES</content>
               </title>
               <text>
                  <paragraph>1. OSHA Hazardous Drugs. OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html</paragraph>
               </text>
               <effectiveTime value="20250312"/>
            </section>
         </component>
         <component>
            <section>
               <id root="03e257fa-359d-41a2-b061-77518db9dc07"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16 </content>
                  <content styleCode="bold">HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph>NDCÂ 71731-4171-1 Â  Â  Â </paragraph>
                  <paragraph>Injection: 1 mg/2 mL, in a single-dose vial. One vial per carton.</paragraph>
                  <paragraph>Store at 20Âº to 25ÂºC (68Âº to 77ÂºF); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) [See USP Controlled Room Temperature]. Do not freeze or refrigerate. Store the vials in their original cartons.</paragraph>
                  <paragraph>Eribulin mesylate injection is colourless and clear liquid.</paragraph>
                  <paragraph>Eribulin mesylateÂ injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.Â¹</paragraph>
               </text>
               <effectiveTime value="20250312"/>
            </section>
         </component>
         <component>
            <section>
               <id root="f2027196-e1cf-49ac-84c4-0d5d343ee012"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="88436-1" displayName="PATIENT COUNSELING INFORMATION"/>
               <title>
                  <content styleCode="bold">17Â </content>
                  <content styleCode="bold">PATIENT COUNSELING INFORMATION</content>
               </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling <linkHtml href="#PATIENTINFORMATION">(Patient Information).</linkHtml>
                  </paragraph>
               </text>
               <effectiveTime value="20250312"/>
               <component>
                  <section ID="L3bf2e234-c005-482e-bd5b-f1100233f8ff">
                     <id root="9a9eb2ad-4cd8-4c17-932b-0b3dca092697"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Neutropenia</content>
                        </paragraph>
                        <paragraph>Advise patients to contact their health care provider for a fever of 100.5Â°F or greater or other signs or symptoms of infection such as chills, cough, or burning or pain on urination <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section ID="L6c0180e4-ae55-4292-acd2-32651197e139">
                     <id root="d3864cb6-b8e3-41cb-a233-c0e9a970f150"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Peripheral Neuropathy</content>
                        </paragraph>
                        <paragraph>Advise patients to inform their healthcare providers of new or worsening numbness, tingling and pain in their extremities <content styleCode="italics">[see Warnings and Precautions (5.2)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section ID="L9e86811c-7eea-413e-87d9-7285412bd9be">
                     <id root="f7ef7090-e5bb-4be9-8412-8b15e8022ae4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Embryo-Fetal Toxicity</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see Warnings and Precautions (5.3),Use in Specific Populations (8.1)]</content>.</item>
                           <item>Advise females of reproductive potential to use effective contraception during treatment with eribulin mesylate injection and for at least 2 weeks after the final dose <content styleCode="italics">[see Use in Specific Populations (8.3)]</content>.</item>
                           <item>Advise males with female partners of reproductive potential to use effective contraception during treatment with eribulin mesylate injection and for 3.5 months following the final dose <content styleCode="italics">[see Use in Specific Populations (8.3)].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section ID="L43736191-b025-43aa-85c0-f908134df618">
                     <id root="d854b423-33f5-478d-a081-649f40bf5b4d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise women not to breastfeed during treatment with eribulin mesylate injection and for 2 weeks after the final dose <content styleCode="italics">[see Use in Specific Populations (8.2)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
               <component>
                  <section ID="Lda6c2bfd-51f7-486a-88a2-a1b51a2b4202">
                     <id root="1d13e171-925e-4a7b-8926-c14aa81be02f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>Manufactured for:<br/>The WhiteOak Group, LLC<br/>Washington DC, 20006<br/>Made in China</paragraph>
                     </text>
                     <effectiveTime value="20250312"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="e477a07d-742a-4fcc-9617-07a5e96eb4b2"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="42230-3" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title/>
               <text>
                  <table ID="PATIENTINFORMATION">
                     <colgroup>
                        <col width="721"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule" align="center">
                              <paragraph>
                                 <content styleCode="bold">PATIENT INFORMATION </content>
                                 <br/>
                                 <content styleCode="bold">eribulin mesylateÂ injection</content>
                              </paragraph>
                              <paragraph>for intravenous use</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">What is the most important information I should know about eribulin mesylate injection?</content>
                              <br/>
                              <content styleCode="bold">Eribulin mesylateÂ can cause serious side effects, including:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Low</content>
                                    <content styleCode="bold"> white blood cell count (neutropenia)</content>. Â This can lead to serious infections that could lead to death. Â Your healthcare provider will check your blood cell counts before you receive each dose ofÂ eribulin mesylate injection and during treatment.Â Â Call your healthcare provider right away if you develop any of these symptoms of infection:<br/>Â°Â fever (temperature above 100.5Â°F)Â Â Â Â Â <br/>Â° chills<br/>Â° cough<br/>Â° burning or pain when you urinate</item>
                                 <item>
                                    <content styleCode="bold">N</content>
                                    <content styleCode="bold">umbness, tingling, or </content>
                                    <content styleCode="bold">pain</content>
                                    <content styleCode="bold">in your hands </content>
                                    <content styleCode="bold">orÂ </content>
                                    <content styleCode="bold">feetÂ </content>
                                    <content styleCode="bold">(</content>
                                    <content styleCode="bold">peripheral </content>
                                    <content styleCode="bold">neuropathy)</content>. Peripheral neuropathy is common withÂ eribulin mesylate injection and sometimes can be severe.Â Â Tell your healthcare provider if you have new or worsening symptoms of peripheral neuropathy.</item>
                                 <item>Your healthcare provider may delay, decrease your dose, or stop treatment withÂ eribulin mesylate injection if you have side effects.</item>
                              </list>See â<content styleCode="bold">What are possible side effects of eribulin mesylate injection?â </content>for more information about side effects<content styleCode="italics">.</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">What is eribulin mesylate injection? </content>
                              <br/>Eribulin Mesylate InjectionÂ is a prescription medicine used to treat people with:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Breast cancer<br/>Â°Â that has spread to other parts of the body, <content styleCode="bold">and</content>
                                    <br/>Â°Â who have already received certain types of anticancer medicines after the cancer has spread</item>
                                 <item>Liposarcoma <br/>Â°Â that cannot be treated with surgery or has spread to other parts of the body, <content styleCode="bold">and</content>
                                    <br/>
                                    <content styleCode="bold">Â°Â </content>who have received treatment with a certain type of anticancer medicine</item>
                              </list>It is not known ifÂ Eribulin Mesylate Injection is safe and effective in children under 18 years of age.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Toprule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Before you receive eribulin mesylate injection, tell your healthcare provider </content>
                              <content styleCode="bold">about all of your medical conditions, including </content>
                              <content styleCode="bold">if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have liver or kidney problems</item>
                                 <item>have heart problems, including a problem called congenital long QT syndrome</item>
                                 <item>have low potassium or low magnesium in your blood</item>
                                 <item>are pregnant or plan to become pregnant.Â  Eribulin mesylate injectionÂ can harm your unborn baby. Â Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with eribulin mesylate injection.<br/>
                                    <content styleCode="bold">Â°Â </content>
                                    <content styleCode="bold">Females</content> who are able to become pregnant should use an effective birth control during treatment withÂ eribulin mesylate injection and for at least 2 weeks after the final dose of eribulin mesylate injection.<br/>
                                    <content styleCode="bold">Â°Â </content>
                                    <content styleCode="bold">Males</content> should use an effective form of birth control when having sex with female partners who are able to become pregnant during treatment withÂ eribulin mesylate injection and for 3 1/2 months (14 weeks) after the final dose of eribulin mesylate injection.</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known ifÂ eribulin mesylate passes into your breast milk. Â Do not breastfeed during treatment withÂ eribulin mesylate injection and for 2 weeks after the final dose of eribulin mesylate injection.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">How will I receive eribulin mesylate injection?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>eribulin mesylate injectionÂ is given by intravenous (IV) injection in your vein.</item>
                                 <item>eribulin mesylate injectionÂ is given in âcyclesâ of treatment, with each cycle lasting 21Â days.</item>
                                 <item>eribulin mesylate injectionÂ is usually given onÂ day 1 and day 8 of a treatment cycle.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">What are the possible side effects of eribulin mesylate injection?</content>
                              <br/>eribulin mesylate injectionÂ may cause serious side effects, including:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>See â<content styleCode="bold">What is the most important information I should know about eribulin mesylate injection?â</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">eribulin mesylate injectionÂ can cause </content>
                                    <content styleCode="bold">changes in your heartbeat (</content>
                                    <content styleCode="bold">called QT prolongation</content>
                                    <content styleCode="bold">).</content> This can cause irregular heartbeats.Â Â Your healthcare provider may do heart monitoring (electrocardiogram or ECG) or blood tests during your treatment withÂ eribulin mesylate injection to check for heart problems.</item>
                              </list>The most common side effects ofÂ eribulin mesylate injection in people with breast cancer include: <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>low white blood cell count (neutropenia)</item>
                                 <item>low red blood cell count (anemia)</item>
                                 <item>weakness or tiredness</item>
                                 <item>hair loss (alopecia)</item>
                                 <item>nausea</item>
                                 <item>constipation</item>
                              </list>The most common side effects ofÂ eribulin mesylate injection in people with liposarcoma include: <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>tiredness</item>
                                 <item>nausea</item>
                                 <item>hair loss (alopecia)</item>
                                 <item>constipation</item>
                                 <item>stomach pain</item>
                                 <item>fever</item>
                              </list>Your healthcare provider will do blood tests before and during treatment while you are taking eribulin mesylate injection. The most common changes to blood tests in people with liposarcoma include:</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>low white blood cell count (neutropenia)</item>
                                 <item>decreased blood levels of potassium or calcium</item>
                              </list>Tell your healthcare provider about any side effect that bothers you or that does not go away.<br/>These are not all the possible side effects of eribulin mesylate injection. Â Call your doctor for medical advice about side effects. Â You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">General information aboutÂ eribulin mesylate injection</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Â You can ask your pharmacist or healthcare provider for information aboutÂ eribulin mesylate injection that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule">
                              <content styleCode="bold">What are the ingredients in eribulin mesylate injection?</content>
                              <br/>
                              <content styleCode="bold">Active Ingredient</content>: eribulin mesylate<br/>
                              <content styleCode="bold">Inactive Ingredients:</content>Â Â dehydrated alcohol, water for injection,Â and sodium hydroxide or hydrochloric acid may be used for pH adjustment. <br/>
                              <br/>Manufactured for:<br/>The WhiteOak Group, LLC<br/>Washington DC, 20006<br/>Made in China</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration.Â  Â Â Â Â Â  Â Â Â Â Â  Â Â Â Â Â  Revised: 12/2023</paragraph>
               </text>
               <effectiveTime value="20250312"/>
            </section>
         </component>
         <component>
            <section>
               <id root="8b8aafb1-f97f-416f-99d1-373358795cab"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>NDCÂ 71731-4171-1<br/>Eribulin Mesylat Injection<br/>1Â mg/2Â mL<br/>(0.5Â mg/mL)<br/>For Intravenous Use</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L4ee6cf7b-84d2-47a7-9496-291491f6b1f1"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250312"/>
               <component>
                  <observationMedia ID="L4ee6cf7b-84d2-47a7-9496-291491f6b1f1">
                     <text>Draft Carton Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Draft Carton Label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="a882b965-dad8-40c1-8ba8-b0d82cfec912"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>NDCÂ 71731-4171-1<br/>Eribulin Mesylate Injection<br/>1Â mg/2Â mL<br/>(0.5Â mg/mL)<br/>For Intravenous Use</paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lf9c7a722-dccc-4d9e-8173-4a842667cc09"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20250307"/>
               <component>
                  <observationMedia ID="Lf9c7a722-dccc-4d9e-8173-4a842667cc09">
                     <text>Draft Container Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Draft Container Label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>